Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 29.1% in October

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 93,600 shares, a growth of 29.1% from the September 30th total of 72,500 shares. Based on an average daily volume of 276,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.7% of the company’s stock are short sold.

Chemomab Therapeutics Price Performance

Shares of CMMB stock opened at $1.44 on Wednesday. The company has a market cap of $15.91 million, a P/E ratio of -0.90 and a beta of 0.52. The stock’s 50-day moving average is $1.64 and its 200 day moving average is $1.20. Chemomab Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.55.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same period in the previous year, the firm earned ($0.72) EPS. On average, analysts anticipate that Chemomab Therapeutics will post -1 EPS for the current year.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).